Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice

Journal of Bone and Mineral Research

Volumn 27, Issue 10, 2012, Pages 2118-2129

  Dieudonné, François Xavier ^a,b   Marion, Allison ^a,b   Marie, Pierre J ^a,b   Modrowski, Dominique ^a,b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

CATENIN; CHEMOSENSITIVITY; FOXO; OSTEOSARCOMA; SYNDECAN 2

Indexed keywords

BETA CATENIN; CYTOTOXIC AGENT; DICKKOPF 1 PROTEIN; DOXORUBICIN; FORKHEAD TRANSCRIPTION FACTOR; SECRETED FRIZZLED RELATED PROTEIN 1; SYNDECAN 2; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR FKHRL1; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE TUMOR; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG SENSITIZATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FORKHEAD TRANSCRIPTION FACTORS; GENE TARGETING; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED BALB C; OSTEOSARCOMA; SYNDECAN-2; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; WNT SIGNALING PATHWAY;

EID: 84866672444     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1650     Document Type: Article

References (37)

1. Gibbs CP Jr, Weber K, Scarborough MT,. Malignant bone tumors. Instr Course Lect. 2002; 51: 413-28.
2. Marina N, Gebhardt M, Teot L, Gorlick R,. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004; 9: 422-41. (Pubitemid 39014554)
3. Tabone MD, Kalifa C, Rodary C, Raquin M, Valteau-Couanet D, Lemerle J,. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol. 1994; 12: 2614-20. (Pubitemid 24379647)
4. Overholtzer M, Rao PH, Favis R, Lu XY, Elowitz MB, Barany F, Ladanyi M, Gorlick R, Levine AJ,. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci U S A. 2003; 100: 11547-52. (Pubitemid 37205973)
5. Tang N, Song WX, Luo J, Haydon RC, He TC,. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res. 2008; 466: 2114-30.
6. Chou AJ, Gorlick R,. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006; 6: 1075-85. (Pubitemid 44203385)
7. Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM, Ramsey KE, Antonescu CR, Chen W, Healey JH, Daluski A, Berens ME, Macdonald TJ, Gorlick R, Stephan DA,. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005; 65: 1748-54. (Pubitemid 40478600)
8. Harisi R, Dudas J, Nagy-Olah J, Timar F, Szendroi M, Jeney A,. Extracellular matrix induces doxorubicin-resistance in human osteosarcoma cells by suppression of p53 function. Cancer Biol Ther. 2007; 6: 1240-6. (Pubitemid 351590378)
9. Jin W, Wu L, Liang K, Liu B, Lu Y, Fan Z,. Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer. 2003; 89: 185-91. (Pubitemid 36897956)
10. Perona R, Sanchez-Perez I,. Signaling pathways involved in clinical responses to chemotherapy. Clin Transl Oncol. 2007; 9: 625-33.
11. Huang JW, Chen CL, Chuang NN,. Trap RACK1 with Ras to mobilize Src signaling at syndecan-2/p120-GAP upon transformation with oncogenic ras. Biochem Biophys Res Commun. 2005; 330: 1087-94.
12. Lin YL, Lei YT, Hong CJ, Hsueh YP,. Syndecan-2 induces filopodia and dendritic spine formation via the neurofibromin-PKA-Ena/VASP pathway. J Cell Biol. 2007; 177: 829-41.
13. Modrowski D, Orosco A, Thevenard J, Fromigue O, Marie PJ,. Syndecan-2 overexpression induces osteosarcoma cell apoptosis: implication of syndecan-2 cytoplasmic domain and JNK signaling. Bone. 2005; 37: 180-9. (Pubitemid 40962425)
14. Orosco A, Fromigue O, Hay E, Marie PJ, Modrowski D,. Dual involvement of protein kinase C delta in apoptosis induced by syndecan-2 in osteoblasts. J Cell Biochem. 2006; 98: 838-50. (Pubitemid 43993400)
15. Orosco A, Fromigue O, Bazille C, Entz-Werle N, Levillain P, Marie PJ, Modrowski D,. Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma. Cancer Res. 2007; 67: 3708-15. (Pubitemid 46762156)
16. Villena J, Mainez J, Noguer O, Contreras H, Granes F, Reina M, Fabregat I, Vilaro S,. Syndecan-2 expression increases serum-withdrawal-induced apoptosis, mediated by re-distribution of Fas into lipid rafts, in stably transfected Swiss 3T3 cells. Apoptosis. 2006; 11: 2065-75. (Pubitemid 44691588)
17. Dieudonne FX, Marion A, Hay E, Marie PJ, Modrowski D,. High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells. Cancer Res. 2010; 70: 5399-408.
18. Guo Y, Rubin EM, Xie J, Zi X, Hoang BH,. Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clin Orthop Relat Res. 2008; 466: 2039-45.
19. Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PF, Simmons PJ, Dawid IB, Thomas DM,. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest. 2009; 119: 837-51.
20. Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM,. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol. 2010; 220: 24-33.
21. Matushansky I, Hernando E, Socci ND, Mills JE, Matos TA, Edgar MA, Singer S, Maki RG, Cordon-Cardo C,. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest. 2007; 117: 3248-57. (Pubitemid 350096982)
22. Bodine PV,. Wnt signaling control of bone cell apoptosis. Cell Res. 2008; 18: 248-53. (Pubitemid 351206161)
23. Furuyama T, Nakazawa T, Nakano I, Mori N,. Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochem J. 2000; 349: 629-34. (Pubitemid 30465799)
24. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L,. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis. 2000; 18: 261-71. (Pubitemid 32269996)
25. Yang JY, Hung MC,. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res. 2009; 15: 752-7.
26. Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, Korswagen HC,. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science. 2005; 308: 1181-4. (Pubitemid 40696437)
27. Hoogeboom D, Essers MA, Polderman PE, Voets E, Smits LM, Burgering BM,. Interaction of FOXO with beta-catenin inhibits beta-catenin/T cell factor activity. J Biol Chem. 2008; 283: 9224-30.
28. Doghman M, Cazareth J, Lalli E,. The T cell factor/beta-catenin antagonist PKF115-584 in hibits proliferation of adrenocortical carcinoma cells. J Clin Endocrinol Metab. 2008; 93: 3222-5.
29. Clasper S, Vekemans S, Fiore M, Plebanski M, Wordsworth P, David G, Jackson DG,. Inducible expression of the cell surface heparan sulfate proteoglycan syndecan-2 (fibroglycan) on human activated macrophages can regulate fibroblast growth factor action. J Biol Chem. 1999; 274: 24113-23.
30. Teixe T, Nieto-Blanco P, Vilella R, Engel P, Reina M, Espel E,. Syndecan-2 and -4 expressed on activated primary human CD4+ lymphocytes can regulate T cell activation. Mol Immunol. 2008; 45: 2905-19.
31. van der Vos KE, Coffer PJ,. FOXO-binding partners: it takes two to tango. Oncogene. 2008; 27: 2289-99. (Pubitemid 351501780)
32. Wang MC, Bohmann D, Jasper H,. JNK extends life span and limits growth by antagonizing cellular and organism-wide responses to insulin signaling. Cell. 2005; 121: 115-25.
33. Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC,. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem. 2007; 282: 27298-305. (Pubitemid 47501978)
34. Almeida M, Ambrogini E, Han L, Manolagas SC, Jilka RL,. Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton. J Biol Chem. 2009; 284: 27438-48.
35. Lee AY, He B, You L, Xu Z, Mazieres J, Reguart N, Mikami I, Batra S, Jablons DM,. Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma. Biochem Biophys Res Commun. 2004; 323: 1246-50. (Pubitemid 39296559)
36. Mikheev AM, Mikheeva SA, Maxwell JP, Rivo JV, Rostomily R, Swisshelm K, Zarbl H,. Dickkopf-1 mediated tumor suppression in human breast carcinoma cells. Breast Cancer Res Treat. 2008; 112: 263-73.
37. Meads MB, Hazlehurst LA, Dalton WS,. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 2008; 14: 2519-26.